InsidersTradesSigma
Discover the detailed record of transactions filed by Newman Michael James, Directeur. Director active across 1 companies, notably Indaptus Therapeutics, Inc.. Aggregated, 2 disclosures have been published. Total volume traded: €53k. The latest transaction was disclosed on 31 January 2022 — Cession. Regulator: SEC (Form 4). The full history is free.
2 of 2 declarations
Michael James Newman serves as a Director and Chief Strategy Officer at Indaptus Therapeutics, Inc. He is responsible for formulating and executing the company's strategy, contributing to the organization's direction and growth. Michael plays a key role in developing innovative therapeutic solutions and leading strategic initiatives.